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Introduction
Interleukin-5 (IL5) was demonstrated to be localized in eosinophils and, to a lesser extent, in mast cells in a recent immunohistochemical study using glycol methacrylate (GMA)-embedded bronchial biopsy specimens from asthmatic patients (1) . The clinical importance of IL5 is demonstrated by the fact that IL5 is a growth and differentiation factor (2), activator (3). and chemoattractant (4) for eosinophils and, as a consequence, is considered a pivotal cytokine in allergen-mediated eosinophilic responses. In the lower airways, increased IL5 mRNA has been reported in the musoca of mild asthmatics (5). In addition, increased concentration of IL5 protein (6) and increased transcription of IL5 has been found in T-cells recovered by bronchoalveolar lavage (BAL.) from allergic asthmatics (7). In the present investigation we wanted to localize the IL5 immunoreactivity by immunoelectron microscopy. We detected IL5 exclusively in the major eosinophil granule population in mucosal biopsy specimens taken from two atopic asthmatic patients. Specifically, IL-5 was present in the electron-dense crystalloid core compartment but not in the surrounding matrix of the secondary granules of eosinophils. Supported 
Materials and Methods
Bronchial Tisues. Bronchial biopsy specimens were obtained by fiberop tic bronchoscopy (Olympus model BF IT; Tokyo, Japan) from the segmental divisions of the main bronchi of two non-smoking atopic asthmatic patients who were receiving bronchodilators only (terbutaline SO0 pg four times a day). The diagnosis of asthma was based on a history of attacks of breathlessness and wheezing without chronic cough or sputum production, according to the criteria of the American Thoracic Society. The two patients were randomly sampled from the Dutch CNSLD study group (8).
The study protocol was approved by the Medical Ethics Committee.
Fixation and Embedding for Imm~oelecuon Micro~opy. Biopsies were immediately placed in ice-cooled isotonic saline and within 2 0 min were fixed in 1% acrolein plus 0.4% glutaraldehyde (in 0.1 M phosphate buffer, pH 7.2, at 0-4°C for 1-4 hr. After fixation the biopsy samples were stored in a sucrose buffer (1 M sucrose in 1.1 M phosphate buffer, pH 7.2) with 1% paraformaldehyde at 0-4°C. The samples were dehydrated and processed 
Results

Bronchial Mucosa
Immunogold labeling of IL-5 was detected within the crystalloid core compartment of more than 90% of the eosinophil secondary granules visualized in ultra-thin sections of several eosinophilic granulocytes in the bronchial mucosa of two atopic asthmatic patients (Figures 1 and 2 ). The surrounding matrix compartment of these eosinophil granules was often electron-lucent. When matrix compartment was visible, it was not detectably labeled for IL-5. Background labeling was negligible. Other eosinophil granule populations (i.e., primary and small granules), as well as lipid bodies, were not labeled for IL-5, nor was nuclear or cytoplasmic staining detected. No staining was observed in mast cells or in T-lymphocytes. These results were confirmed by two other anti-human IL-5 antibodies [monoclonal mouse IgGl anti-human I L 5 (#2374-01) and polyclonal rabbit anti-human IL-5 (#1722-011)) from Genzyme (Cambridge, MA).
-
Specz9city Controls
Omission of the primary antibody or substitution with an irrelevant IgGl antibody PSAIER-PRS resulted in absence of gold labeling of the eosinophil granules (Figure 3) 
Discussion
This study demonstrates that pre-formed IL5 was localized by immunogold labeling to the crystalloid core compartment of the major secondary or specific granule population of eosinophils in the bronchial mucosa of two atopic asthmatic patients. In contrast. the surrounding matrix compartment of these granules did not label for IL5. No labeling was detected in other organelles of the eosinophils, nucleus, or cytoplasm.
IL5 mRNA has been previously reported in eosinophils (lO,ll), and in an immunohistochemical study using GMA-embedded bronchial biopsies IL5 protein has been detected in eosinophils (1). Our ultrastructural localization of IL5 suggested that the presence of IL5 in stored forms in the secondary granules of eosinophils would provide a ready source of this cytokine in response to allergen stimulation. No staining was observed in mast cells or in T-lymphocytes. However, this does not mean that these cells are not producing and secreting IL-5. It is likely that once generated, T-cells immediately secrete IL-5. In contrast with eosinophils, lymphocytes have little capacity for mediator storage.
Eosinophils have recently been identified as a pivotal source of several other cytokines in addition to IL5, including &la (12), IL3 (U), IL6 (14), IL-8 (15), GM-CSF (16), TNF-a (17) , MIP-la (18), TGF-a (19, and TGF-0 (20) . However, the substructural location of most of these cytokines remains to be determined.
Ultrastructural immunohistochemical techniques with goldconjugated secondary antibodies have made it possible to identify subcellular sites for a variety of eosinophil constituents (21) . Four different basic proteins with cytotoxic properties and a number of enzymes are recognized in the specific eosinophil granules (22). The crystalline core compartment consists of major basic protein (MBP), and the surrounding matrix is composed of eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), and eosinophil peroxidase (EPO).
Although the distribution of these eosinophil granule proteins has been known for some time, the ultrastructural localization of IL5 in the cystalloid core of the secondary granules of eosinophils in bronchial mucosa of asthmatic patients has not previously been determined.
